|
US20040009169A1
(en)
*
|
2002-02-25 |
2004-01-15 |
Julie Taylor |
Administration of agents for the treatment of inflammation
|
|
ES2614274T3
(es)
*
|
2002-09-06 |
2017-05-30 |
Alexion Pharmaceuticals, Inc. |
Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
HUE051878T2
(hu)
|
2003-02-10 |
2021-03-29 |
Biogen Ma Inc |
Immunglobulin készítmény és annak elõállítási módszere
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
AU2005231822B2
(en)
*
|
2004-04-02 |
2011-07-21 |
Swedish Orphan Biovitrum Ab (Publ) |
Methods of reducing aggregation of IL-1ra
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1827491A4
(en)
*
|
2004-11-19 |
2010-07-14 |
Biogen Idec Inc |
TREATMENT OF MULTIPLE SCLEROSIS
|
|
DK2620450T3
(en)
*
|
2005-03-08 |
2019-02-04 |
Pfizer Prod Inc |
Antibody Compositions against CTLA-4
|
|
CA2607663C
(en)
*
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
CA2625815A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-cd3 antibody formulations
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
|
AU2007225044C1
(en)
|
2006-03-15 |
2018-03-29 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
WO2008039761A2
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
CL2007002880A1
(es)
*
|
2006-10-06 |
2008-05-09 |
Amgen Inc |
Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
|
|
TW200833357A
(en)
*
|
2006-10-20 |
2008-08-16 |
Amgen Inc |
Stable polypeptide formulations
|
|
AR064826A1
(es)
*
|
2007-01-09 |
2009-04-29 |
Wyeth Corp |
Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
|
|
JP5303792B2
(ja)
*
|
2007-02-12 |
2013-10-02 |
ボウジベル，ラサアド |
保存料を含まないスクラロース無菌溶液
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
AR067011A1
(es)
*
|
2007-06-14 |
2009-09-30 |
Biogen Idec Inc |
Formulaciones de anticuerpos
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
JP5081976B2
(ja)
*
|
2007-10-22 |
2012-11-28 |
ベクトン・ディキンソン・アンド・カンパニー |
オルガノポリシロキサンを含む懸濁液においてタンパク質の凝集を評価するための方法
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI532498B
(zh)
|
2008-03-17 |
2016-05-11 |
巴克斯特保健公司 |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
AU2009236305B2
(en)
|
2008-04-15 |
2014-04-10 |
Grifols Therapeutics Inc. |
Two-stage ultrafiltration/diafiltration
|
|
US8263748B2
(en)
|
2008-08-27 |
2012-09-11 |
Schering Corporation |
Lyophilized formulations of engineered anti-IL-23p19 antibodies
|
|
TWI445716B
(zh)
*
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Ｐｃｓｋ９拮抗劑類
|
|
CN104398471A
(zh)
*
|
2008-11-28 |
2015-03-11 |
Abbvie公司 |
稳定的抗体组合物和用于稳定其的方法
|
|
EP2381929B1
(en)
*
|
2008-12-29 |
2015-07-08 |
Samyang Biopharmaceuticals Corporation |
Pharmaceutical composition of lyophilized formulation and preparation method of the same
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
WO2010121141A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
|
CN104490767A
(zh)
*
|
2009-05-04 |
2015-04-08 |
艾伯维生物技术有限公司 |
人抗TNF-α抗体的稳定高蛋白质浓度制剂
|
|
DK2477603T3
(en)
*
|
2009-09-17 |
2016-06-13 |
Baxalta Inc |
STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
|
|
HRP20190690T1
(hr)
*
|
2009-10-09 |
2019-06-28 |
Armagen, Inc. |
Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
WO2011104381A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
US20140161794A1
(en)
|
2010-04-16 |
2014-06-12 |
Biogen Idec Ma Inc. |
Anti-vla-4 antibodies
|
|
MX2012013586A
(es)
|
2010-05-28 |
2013-01-24 |
Novo Nordisk As |
Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
|
|
MX2012013664A
(es)
|
2010-06-04 |
2013-01-24 |
Wyeth Llc |
Formulaciones de vacuna.
|
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
JP2013544762A
(ja)
|
2010-09-17 |
2013-12-19 |
バクスター、インターナショナル、インコーポレイテッド |
弱酸性〜中性のｐＨにおける、塩化ナトリウムを有する水性製剤を介した免疫グロブリンおよび他のタンパク質の安定化
|
|
MX2013003681A
(es)
|
2010-10-01 |
2013-11-20 |
Moderna Therapeutics Inc |
Ácidos nucleicos manipulados y métodos de uso de los mismos.
|
|
PT3722808T
(pt)
|
2010-10-25 |
2024-12-09 |
Biogen Ma Inc |
Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam
|
|
TWI606840B
(zh)
|
2010-11-11 |
2017-12-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
KR20190116563A
(ko)
|
2011-03-31 |
2019-10-14 |
머크 샤프 앤드 돔 코포레이션 |
인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
WO2012160199A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Glaxosmithkline Biologicals Sa |
Inactivated dengue virus vaccine
|
|
EA026226B1
(ru)
*
|
2011-07-01 |
2017-03-31 |
Байоджен Айдек Ма Инк. |
Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
SMT202200355T1
(it)
|
2011-12-16 |
2022-11-18 |
Modernatx Inc |
Composizioni di mrna modificato
|
|
JO3533B1
(ar)
*
|
2012-01-23 |
2020-07-05 |
Regeneron Pharma |
تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
|
|
PL2830658T3
(pl)
*
|
2012-03-26 |
2019-02-28 |
Sanofi |
Stabilne formulacje środków wiążących lgG4
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2834260A4
(en)
|
2012-04-02 |
2016-08-10 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
LT3041513T
(lt)
|
2013-09-08 |
2020-11-25 |
Kodiak Sciences Inc. |
Viii faktoriaus cviterioninių polimerų konjugatai
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
HUE068207T2
(hu)
|
2013-11-21 |
2024-12-28 |
Genmab As |
Antitest-drog konjugátumkészítmény
|
|
WO2015095568A1
(en)
*
|
2013-12-18 |
2015-06-25 |
Kelvin Lee |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
TWI752912B
(zh)
*
|
2015-07-17 |
2022-01-21 |
美商寇西勒斯生物科技股份有限公司 |
那他珠單抗的穩定水性調配物
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
|
KR20180101479A
(ko)
|
2016-01-13 |
2018-09-12 |
젠맵 에이/에스 |
항체 및 그의 약물 접합체를 위한 제제
|
|
ES2797298T3
(es)
|
2016-02-10 |
2020-12-01 |
Becton Dickinson France |
Procedimiento para evaluar la estabilidad de una formulación a base de proteína
|
|
WO2018091729A2
(en)
|
2016-11-21 |
2018-05-24 |
Zaklady Farmaceutyczne Polpharma Sa |
Aqueous pharmaceutical formulations
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
EP3459527B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
|
PE20201338A1
(es)
|
2017-12-06 |
2020-11-25 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
|
|
AU2018380979B2
(en)
*
|
2017-12-08 |
2023-07-20 |
argenx BV |
Use of FcRn antagonists for treatment of generalized myasthenia gravis
|
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
WO2019169341A1
(en)
|
2018-03-02 |
2019-09-06 |
Kodiak Sciences Inc. |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
CA3092551A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
EP3761953A1
(en)
|
2018-03-08 |
2021-01-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
EP3773696A4
(en)
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Stable formulations of therapeutic antibody
|
|
WO2019198099A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Dr. Reddy's Laboratories Limited |
Stable antibody formulation
|
|
SG11202009874QA
(en)
*
|
2018-04-10 |
2020-11-27 |
Dr Reddys Laboratories Ltd |
Antibody formulation
|
|
SG11202010993VA
(en)
|
2018-05-07 |
2020-12-30 |
Genmab As |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
US12037398B2
(en)
|
2018-06-04 |
2024-07-16 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies having reduced effector function
|
|
MX2020013195A
(es)
|
2018-06-08 |
2021-02-26 |
Argenx Bvba |
Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
|
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
EP3810094A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
EP3811962A4
(en)
*
|
2018-06-25 |
2022-03-16 |
JCR Pharmaceuticals Co., Ltd. |
Protein-containing aqueous liquid formulation
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
MX2021005394A
(es)
|
2018-11-07 |
2021-07-06 |
Merck Sharp & Dohme Llc |
Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
|
|
US11548941B2
(en)
|
2018-11-20 |
2023-01-10 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
|
GEAP202415690A
(en)
|
2018-12-19 |
2024-01-10 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
JP7555929B2
(ja)
*
|
2018-12-24 |
2024-09-25 |
遠大賽威信生命科学（南京）有限公司 |
Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
|
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
|
MX2021014756A
(es)
*
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
|
|
KR20220019756A
(ko)
*
|
2019-06-11 |
2022-02-17 |
마크로제닉스, 인크. |
이중특이적 디아바디의 제약학적 제제 및 그것의 용도
|
|
JP2022542430A
(ja)
*
|
2019-08-01 |
2022-10-03 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｆｃｒｎ抗体およびその使用の方法
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
|
US20230041642A1
(en)
*
|
2019-12-16 |
2023-02-09 |
Nipro Corporation |
Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
|
|
CN115836086A
(zh)
|
2020-01-08 |
2023-03-21 |
阿尔金克斯有限公司 |
治疗天疱疮病症的方法
|
|
US20230151102A1
(en)
*
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
AU2021213153A1
(en)
*
|
2020-01-29 |
2022-08-04 |
Merck Sharp & Dohme Llc |
Methods of separating host cell lipases from an anti-LAG3 antibody production
|
|
KR20230023663A
(ko)
|
2020-05-21 |
2023-02-17 |
얀센 바이오테크 인코포레이티드 |
Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
|
|
EP4243859A4
(en)
*
|
2020-11-12 |
2024-10-16 |
Dr. Reddy's Laboratories Ltd. |
STABLE AQUEOUS FORMULATION WITH HIGH CONCENTRATION OF ANTI-INTEGRIN ANTIBODY
|
|
IL315065A
(en)
|
2022-03-14 |
2024-10-01 |
LamKap Bio gamma AG |
GPC3XCD28 and GPC3XCD3 bispecific antibodies and their combination for targeted killing of GPC3-positive malignant cells
|
|
AU2023290529A1
(en)
|
2022-06-15 |
2024-12-12 |
argenx BV |
Fcrn/antigen-binding molecules and methods of use
|
|
AU2024282654A1
(en)
|
2023-05-30 |
2025-12-04 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|